Francesco Ramundo
Overview
Explore the profile of Francesco Ramundo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
240
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramundo F, Rossi E, Peris K, Pontecorvi A, Sani G, Betti S, et al.
Curr Med Res Opin
. 2025 Jan;
41(2):239-245.
PMID: 39882590
Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for...
2.
Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco G, et al.
Br J Haematol
. 2024 Oct;
205(6):2287-2294.
PMID: 39375955
We investigated the effect of Ropeginterferon alfa-2b (Ropeg) versus phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients randomized in the low-polycythaemia vera (PV) phase II trial. Patients with...
3.
Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, et al.
Ann Hematol
. 2023 Dec;
103(2):437-442.
PMID: 38060001
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 µg every 2 weeks for 2 years was more effective than the standard treatment of therapeutic phlebotomy...
4.
Carobbio A, Vannucchi A, De Stefano V, Masciulli A, Guglielmelli P, Loscocco G, et al.
Blood Cancer J
. 2022 Feb;
12(2):28.
PMID: 35145055
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP...
5.
Guglielmelli P, Loscocco G, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al.
Blood Cancer J
. 2021 Dec;
11(12):199.
PMID: 34897288
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality. In this regard,...
6.
Loscocco G, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al.
Am J Hematol
. 2021 Aug;
96(11):1472-1480.
PMID: 34424575
The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive of inferior myelofibrosis-free survival (MFS) in WHO-defined essential thrombocythemia...
7.
Gresele P, Momi S, Marcucci R, Ramundo F, De Stefano V, Tripodi A
Haematologica
. 2021 Aug;
106(12):3034-3045.
PMID: 34407607
The COVID-19 pandemic has had a heavy impact on global health and economy and vaccination remains the primary way of controlling the infection. During the ongoing vaccination campaign some unexpected...
8.
Bellesi S, Metafuni E, Hohaus S, Maiolo E, Marchionni F, DInnocenzo S, et al.
Br J Haematol
. 2020 Jul;
191(2):207-211.
PMID: 32679621
A low count of CD4 and CD8 lymphocytes is a hallmark laboratory finding in the coronavirus disease 2019 (COVID-19). Using flow cytometry, we observed significantly higher CD95 (Fas) and PD-1...
9.
Zini G, Bellesi S, Ramundo F, dOnofrio G
Am J Hematol
. 2020 Apr;
95(7):870-872.
PMID: 32279346
No abstract available.